Estrogen may kill prostate cancer
Wednesday, March 3rd, 2010 Posted in hormone therapy | No Comments »The usual way prostate cancer is treated is by withdrawing male hormone testosterone from the patient. The problem is while this kills most of the cells, the few that remain lead to recurrent, incurable disease. Recently, researchers have suggested an unexpected ...
New way to treat castrate resistant cells in prostate cancer patients
Friday, February 26th, 2010 Posted in hormone therapy | No Comments »Biomedical scientists Monash University, Australia, have identified a new way to treat castrate resistant cells in prostate cancer sufferers. For more than 60 years the main way to treat the most common cancer in Australian men has involved removing the hormones ...
Androgen deprivation therapy can increase heart risk factors
Sunday, February 7th, 2010 Posted in hormone therapy | No Comments »According to a science advisory published in Circulation: Journal of the American Heart Association, (AHA), androgen deprivation therapy (ADT), commonly used in prostate cancer treatment, can worsen heart risk factors and may increase the risk of heart attack and/or cardiac ...
Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy
Sunday, January 24th, 2010 Posted in hormone therapy, radiation therapy | No Comments »Discrepancies exist regarding the impact of neoadjuvant hormone therapy (NHT) on the risk of all-cause mortality (ACM) in men who receive brachytherapy for localized prostate cancer. Therefore, the latest study at Harvard Radiation Oncology Program, Boston, Massachusetts targeted to examine ...
New drugs in metastatic castration-resistant prostate cancer
Saturday, January 16th, 2010 Posted in hormone therapy | No Comments »Despite that greater knowledge of prostate cancer biology has led to the isolation of many new and promising targets, treatment of metastatic prostate cancer is still challenging. According to a new review at Institut Gustave-Roussy,Villejuif, France. new agents targeting these molecules ...
Aspirin combined with hormone can shorten lives of prostate cancer patients
Monday, January 11th, 2010 Posted in hormone therapy, prostate cancer risks | No Comments »A new research at Brigham & Women's Hospital and the Dana-Farber Cancer Institute, both in Boston, suggests that men undergoing hormone therapy for prostate cancer who take baby aspirin to protect their heart run a significantly higher risk of dying. Hormonal ...
A holistic approach to androgen deprivation therapy
Saturday, January 2nd, 2010 Posted in hormone therapy | No Comments »Urologists think that it is time to treating the cancer without hurting the patient. They know that androgen deprivation therapy (ADT) for advanced prostate cancer can be linked with side effects which may negatively influence quality of life (QoL) and ...
A new treatment option for patients with advanced prostate cancer
Monday, December 28th, 2009 Posted in hormone therapy | No Comments »Degarelix (Firmagon is a new GnRH blocker that has recently been approved by the EMEA and US FDA for the treatment of men with hormone-sensitive advanced prostate cancer. Gonadotrophin-releasing hormone (GnRH) receptor blockers (antagonists) are the latest addition to the hormonal ...
Posssible new treatments for hormone-resistant prostate cancer
Thursday, December 17th, 2009 Posted in hormone therapy | No Comments »Prostate cancer patients with advanced disease are often treated with hormones. A new thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden reveals that when the tumours start growing again they have more and different blood vessels. Late in ...
Androgen deprivation therapy associated to higher risk for diabetes and heart disease
Saturday, December 12th, 2009 Posted in hormone therapy | No Comments »According to a new study published online December 7 in the Journal of the National Cancer Institute, men of all ages treated for prostate cancer with androgen deprivation therapy, specifically with gonadotropin-releasing hormone agonists (GnRH), have an increased risk of ...